Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

In this Innovation Spotlight, Emmanuel Naouri, associate director of Product Management, NGS Benchtop Systems at Illumina, discusses how the MiSeq i100 Series of sequencers was designed to meet the ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

To be successful, health care organizations ... Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 ...

Massey Genome Service (MGS) has invested in two Illumina MiSeq™ instruments. We offer Illumina MiSeq™ sequencing with the following applications: Send the Massey Genome Service (MSG) an email about ...

Full or partial Illumina MiSeq runs available for customer created libraries. Additionally plasmids or other double-stranded DNA samples can be submitted for a service called “WideSeq”, WideSeq ...

NORTHAMPTON, MA / ACCESS Newswire / January 22, 2025 / Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than ...

NORTHAMPTON, MA / ACCESS Newswire / January 22, 2025 / Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 ...